Leal Therapeutics raises $30m to fund schizophrenia and ALS trials

Leal Therapeutics has completed a $30m extension of its Series A financing to support advancement of its investigational therapies for schizophrenia and ALS through clinical trials.

The post Leal Therapeutics raises $30m to fund schizophrenia and ALS trials appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.